India has retained its position as the third largest investor in Britain, according to official UK government figures released on Tuesday (August 30).
The US remains the biggest source of inward investment, accounting for 570 projects, and China grabs the second spot with 156 projects, the UK’s Department for International Trade data showed.
The latest investment figures come as a boost following the Brexit vote in June, as the country emerged as the most popular destination in the European Union for overseas firms.
The UK recorded a total of 2,213 inward investment projects, up 11 per cent on the previous year, with 116,000 jobs “created or safeguarded” by overseas investment last year.
“These impressive results show the UK continues to be the place to do business. We’ve broadened our reach with emerging markets across the world to cement our position as the number one destination in Europe for investment,” said UK international trade secretary Dr Liam Fox, who was in India this week to hold talks with finance minister Arun Jaitley and commerce minister Nirmala Sitharaman.
“The UK-India partnership lies at the very heart of the strategic relationship between our two nations, a relationship that has never been more important than it is today,” he said.
Britain cannot engage in formal trade talks with other nations while it remains a member of the EU but informal talks on the idea of future deals can be discussed.
Once Article 50 is invoked and the official process for Britain’s exit from the economic bloc is set in motion, the UK is reportedly keen to strike pacts with emerging markets like India and China.
While in India, Fox also met major Indian firms in the information technology sector including HCL and Tech Mahindra.
“The UK is the investment destination of choice for Indian ICT companies, and the secretary of state [Fox] discussed future investment opportunities in the UK,” his department said in a statement on Tuesday.
This is the fourth visit by a British minister to India since Theresa May took over as prime minister in July.
Last month, UK secretary of state for business and energy Greg Clark and secretary of state for international development Priti Patel visited India.
Another Indian-origin minister Alok Sharma, who took charge as minister for Asia in the UK Foreign Office, was the first to make a tour of India last month.
UK life sciences sector contributed £17.6bn GVA in 2021 and supports 126,000 high-skilled jobs.
Inward life sciences FDI fell by 58 per cent from £1,897m in 2021 to £795m in 2023.
Experts warn NHS underinvestment and NICE pricing rules are deterring innovation and patient access.
Investment gap
Britain is seeking to attract new pharmaceutical investment as part of its plan to strengthen the life sciences sector, Chancellor Rachel Reeves said during meetings in Washington this week. “We do need to make sure that we are an attractive place for pharmaceuticals, and that includes on pricing, but in return for that, we want to see more investment flow to Britain,” Reeves told reporters.
Recent ABPI report, ‘Creating the conditions for investment and growth’, The UK’s pharmaceutical industry is integral to both the country’s health and growth missions, contributing £17.6 billion in direct gross value added (GVA) annually and supporting 126,000 high-skilled jobs across the nation. It also invests more in research and development (R&D) than any other sector. Yet inward life sciences foreign direct investment (FDI) fell by 58per cent, from £1,897 million in 2021 to £795 million in 2023, while pharmaceutical R&D investment in the UK lagged behind global growth trends, costing an estimated £1.3 billion in lost investment in 2023 alone.
Richard Torbett, ABPI Chief Executive, noted “The UK can lead globally in medicines and vaccines, unlocking billions in R&D investment and improving patient access but only if barriers are removed and innovation rewarded.”
The UK invests just 9% of healthcare spending in medicines, compared with 17% in Spain, and only 37% of new medicines are made fully available for their licensed indications, compared to 90% in Germany.
Expert reviews
Shailesh Solanki, executive editor of Pharmacy Business, pointed that “The government’s own review shows the sector is underfunded by about £2 billion per year. To make transformation a reality, this gap must be closed with clear plans for investment in people, premises and technology.”
The National Institute for Health and Care Excellence (NICE) cost-effectiveness threshold £20,000 to £30,000 per Quality-Adjusted Life Year (QALY) — has remained unchanged for over two decades, delaying or deterring new medicine launches. Raising it is viewed as vital to attracting foreign investment, expanding patient access, and maintaining the UK’s global standing in life sciences.
Guy Oliver, General Manager for Bristol Myers Squibb UK and Ireland, noted that " the current VPAG rate is leaving UK patients behind other countries, forcing cuts to NHS partnerships, clinical trials, and workforce despite government growth ambitions".
Reeves’ push for reform, supported by the ABPI’s Competitiveness Framework, underlines Britain’s intent to stay a leading hub for pharmaceutical innovation while ensuring NHS patients will gain faster access to new treatments.
By clicking the 'Subscribe’, you agree to receive our newsletter, marketing communications and industry
partners/sponsors sharing promotional product information via email and print communication from Garavi Gujarat
Publications Ltd and subsidiaries. You have the right to withdraw your consent at any time by clicking the
unsubscribe link in our emails. We will use your email address to personalize our communications and send you
relevant offers. Your data will be stored up to 30 days after unsubscribing.
Contact us at data@amg.biz to see how we manage and store your data.